2020
Medical marijuana certification for patients with sickle cell disease: a report of a single center experience
Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.Peer-Reviewed Original ResearchConceptsOpioid useMedical marijuanaSickle cell disease (SCD) reportBaseline opioid useSingle-center experienceHealth care utilizationSickle cell diseaseOpioid utilizationClinical characteristicsMost patientsCenter experienceCare utilizationSCD patientsInpatient hospitalizationRandom patientsAdmission ratesCell diseasePatientsRetrospective dataDisease reportsStudy periodHealth careCannabis productsCannabisEdible cannabis productsUtilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program
Rousseau R, Weisberg DF, Gorero J, Parwani V, Bozzo J, Kenyon K, Smith C, Cole J, Curtis S, Forray A, Roberts JD. Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program. PLOS ONE 2020, 15: e0236360. PMID: 32706825, PMCID: PMC7380627, DOI: 10.1371/journal.pone.0236360.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCell diseaseYale-New Haven HospitalAcute care servicesCare of adultsPoor socio-economic statusPersonalized care planSickle Cell ProgramNew Haven HospitalSingle nursing unitParenteral opioidsPain controlClinic visitsMost patientsPain managementChronic painOutpatient visitsPrimary complaintEmergency departmentPrimary careInpatient daysCare plansCare servicesSocio-economic statusNursing units
2006
Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma
Roberts JD, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG. Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma. Journal Of Immunotherapy 2006, 29: 95-101. PMID: 16365605, DOI: 10.1097/01.cji.0000195295.74104.ad.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCancer VaccinesDose-Response Relationship, DrugFemaleGp100 Melanoma AntigenHumansInterleukin-2Leukocytes, MononuclearMaleMelanomaMembrane GlycoproteinsMiddle AgedNeoplasm Recurrence, LocalPeptide FragmentsPeptidesSkin NeoplasmsConceptsLow-dose IL-2G209-2MG209-2M peptideHigh-dose IL-2Phase 2 studyAdvanced melanomaInterleukin-2T cellsHigh-dose interleukin-2Low-dose interleukin-2Melanoma tumor-infiltrating lymphocytesGrade 4 toxicityMelanoma peptide vaccineSubcutaneous IL-2Grade 2 toxicityGrade 3 toxicityTumor-infiltrating lymphocytesEnzyme-linked immunospotHuman leukocyte antigenDifferent toxicity profilesM peptideSignificant biologic effectsTetramer analysisToxic deathsMost patients
2003
RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy
Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, Roberts JD, Shipley WU. RTOG 97-06: Initial report of a Phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: 665-672. PMID: 14529770, DOI: 10.1016/s0360-3016(03)00718-1.Peer-Reviewed Original ResearchMeSH KeywordsAlgorithmsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Transitional CellChemotherapy, AdjuvantCisplatinCombined Modality TherapyConfidence IntervalsCystectomyFemaleHumansMaleMethotrexateMiddle AgedMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingRadiation-Sensitizing AgentsRadiotherapyRemission InductionUrinary Bladder NeoplasmsVinblastineConceptsGrade 3 toxicityAdjuvant chemotherapyInduction therapyOverall survivalResidual diseaseAdditional adjuvant chemotherapyBladder-sparing treatmentCycles of methotrexateGrade 4 hydronephrosisGrade 4 neutropeniaSelective bladder conservationEvidence of diseaseClinical T stagePositive cytologic findingsAggressive transurethral resectionRTOG 97Surgery specimenKarnofsky scoreLocoregional controlLocoregional failureCombination cisplatinMost patientsPathologic reviewProtocol treatmentVinblastine chemotherapy